Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22413339 | 1.00 | NR1H2 (0.49) | NR1H2HPGDALDH1A1MAPTMEN1 | |
| SCHEMBL22413340 | 1.00 | NR1H2 (0.49) | NR1H2HPGDALDH1A1MAPTMEN1 | |
| SCHEMBL2251816 | 1.00 | NR1H2 (0.49) | NR1H2HPGDALDH1A1MAPTMEN1 | |
| SCHEMBL7387263 | 0.90 | HPGD (0.43) | NR1H2HPGDALDH1A1MAPTMEN1 | |
| SCHEMBL855309 | 0.90 | HPGD (0.43) | NR1H2HPGDALDH1A1MAPTMEN1 | |
| SCHEMBL8197412 | 0.90 | HPGD (0.43) | NR1H2HPGDALDH1A1MAPTMEN1 | |
| SCHEMBL12356485 | 0.90 | HPGD (0.43) | NR1H2HPGDALDH1A1MAPTMEN1 | |
| SCHEMBL7387261 | 0.90 | HPGD (0.43) | NR1H2HPGDALDH1A1MAPTMEN1 | |
| SCHEMBL6775860 | 0.90 | HPGD (0.43) | NR1H2HPGDALDH1A1MAPTMEN1 | |
| SCHEMBL13349281 | 0.90 | HPGD (0.43) | NR1H2HPGDALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144841-A1 | TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE | 2022-05-12 | — | — | US | disclosed |
| WO-2020186196-A1 | TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| WO-2009105717-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-08-27 | — | — | WO | disclosed |
| EP-0880500-B1 | ESTERS OF 3-HYDROXY-PIPERIDINEMETHANOL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2002-07-31 | — | — | EP | disclosed |
| US-6096761-A | REACTING A N-SUBSTITUTED 4-METHANOL-3-HYDROXY OR ALKOXY-PIPERIDINE INTERMEDIATE WITH A CARBOXYLIC ACID DERIVATIVES; ADMINISTERING TO AN ANIMAL SUFFERING WITH A CONDITION RELATED TO HAMPERED OR IMPAIRED GASTRIC EMPTYING | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-08-01 | — | — | US | disclosed |
| EP-0880500-A1 | ESTERS OF 3-HYDROXY-PIPERIDINEMETHANOL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997030031-A1 | ESTERS OF 3-HYDROXY-PIPERIDINEMETHANOL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | NR1H2 39/4885HPGD 1169/4885ALDH1A1 1462/4885 |
| US-20220144841-A1 | TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS | CDK7, CDK8, CDK3 | NR1H2 3313/4885HPGD 3011/4885ALDH1A1 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.